Trexquant Investment LP Buys 90,233 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Trexquant Investment LP raised its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 52.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 261,184 shares of the company’s stock after purchasing an additional 90,233 shares during the period. Trexquant Investment LP owned 0.20% of Centessa Pharmaceuticals worth $4,375,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Jane Street Group LLC bought a new stake in Centessa Pharmaceuticals during the third quarter valued at $2,834,000. Wellington Management Group LLP acquired a new stake in Centessa Pharmaceuticals during the third quarter worth approximately $1,609,000. State Street Corp bought a new stake in Centessa Pharmaceuticals in the third quarter worth approximately $777,000. Franklin Resources Inc. boosted its holdings in shares of Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after buying an additional 1,145,823 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter worth approximately $4,305,000. 82.01% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Karen M. Anderson sold 30,526 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $19.03, for a total transaction of $580,909.78. Following the completion of the sale, the insider now directly owns 54,322 shares of the company’s stock, valued at $1,033,747.66. This trade represents a 35.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider David M. Chao sold 7,000 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $17.17, for a total transaction of $120,190.00. Following the completion of the transaction, the insider now directly owns 225,007 shares in the company, valued at $3,863,370.19. This trade represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 260,168 shares of company stock valued at $4,309,568 over the last three months. Corporate insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $11.68 on Friday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.56 billion, a PE ratio of -7.63 and a beta of 1.53. The stock’s fifty day simple moving average is $16.18 and its two-hundred day simple moving average is $16.33. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. As a group, analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CNTA has been the topic of several research analyst reports. Morgan Stanley reissued an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Piper Sandler began coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an “overweight” rating and a $38.00 price objective for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $27.71.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.